PhRMA DTC Principles Call For End Of Reminder Ads
This article was originally published in The Pink Sheet Daily
Executive Summary
Independent review panel will be established to handle complaints about pharmaceutical advertising.
You may also be interested in...
FDAAA’s First Advertising Victim Is MedImmune’s FluMist
“Reminder” newspaper ad actually makes claims and lacks toll-free number for reporting side effects, FDA says.
FDAAA’s First Advertising Victim Is MedImmune’s FluMist
“Reminder” newspaper ad actually makes claims and lacks toll-free number for reporting side effects, FDA says.
Rozerem DTC Ad Suggests Insomnia Drug Is Indicated In Children - FDA
Takeda's direct-to-consumer TV ad for the insomnia drug Rozerem (ramelteon) fails to disclose the drug's indication, does not include information related to side effects and suggests through "back to school"-themed images and statements that the drug is indicated in children, FDA says in a warning letter issued to the company March 5 and posted online March 8